Twist Bioscience heads into the aftermath of its August 3 earnings print with a sharp post-results rally running headlong into one of the most stubborn short positions in biotech.
The stock jumped 8.6% on the day of results, closing Tuesday at $99.45 after a 12.3% gain on the week. That move cuts against a short base that has barely budged. Short interest remains at 23.5% of free float — still close to mid-year highs, with the official FINRA settlement figure of 14.1 million shares confirming the estimate. What makes the setup notable is that shorts have not capitulated. Over the past month, the position actually shrank by 15%, dropping from roughly 16.8 million shares in late June to 14.4 million today — but that drawdown happened before the earnings rally, not because of it. Over the past week, short interest ticked up 0.75%. Bears are adding back, not covering.
The borrow market tells a much looser story. Availability runs at 327%, meaning there are more than three shares available to borrow for every one currently on loan. Cost to borrow is a negligible 0.42%. Neither of those readings suggests any near-term squeeze pressure. Options traders are equally unfazed by downside risk — the put/call ratio is 0.29, well below its 20-day average of 0.34, placing the reading about 0.7 standard deviations on the bullish side. Taken together, positioning looks like a stock where bears have conviction but the lending market has not confirmed urgency.
The analyst community reacted swiftly to the print. Piper Sandler raised its target to $115 from $85 on August 5, maintaining Overweight. Baird lifted to $115 from $113, keeping Outperform. Those moves arrive on top of a wave of target increases over the past two months — Canaccord raised to $120 in mid-July, Guggenheim to $107, Barclays to $95 — all maintaining positive ratings. The lone dissent came from Evercore ISI, which downgraded to In-Line in early July while still lifting its target to $102. The mean analyst target now sits at $100.89, fractionally above the current price, suggesting the Street has been chasing a stock that has moved faster than consensus expected. Factor scores add nuance: EPS surprise ranks in the 95th percentile of the ORTEX universe, and 30-day EPS momentum hits the 84th percentile — both confirming that the fundamental picture has been beating expectations. The short score, however, sits at 68.8 out of 100 and has been creeping higher all week, a composite signal that short-side conviction remains elevated despite the rally.
The bull case centres on Twist's position as a DNA synthesis infrastructure play in the AI-driven wet lab and drug discovery market — a story the company has executed on with enough consistency to generate a run of earnings beats. The bear case is narrower but not trivial: heavy dependence on the NGS segment, a path to profitability that still shows a negative EV/EBITDA of -65x and a PE of -112x, and a founder/CEO who sold $1.79 million of stock in late June near $95. The CFO and President/COO also sold smaller positions in July. None of these are large relative to total shares, and none carry high significance scores, but the direction is uniform — no insider has bought in the trailing 90-day window covered by the data.
Institutional ownership reinforces the bifurcated picture. ARK Investment Management holds 10.2% of shares with no change reported through July 31 — a passive endorsement of the bull case. Artisan Partners holds another 10.2%, adding 537,000 shares in Q1. Farallon Capital entered with a near-clean-slate position of 1.43 million shares in Q1. Against that buying sits the short base, which at 23.5% of float represents a meaningful share of the outstanding register. The next catalyst is a long way off — the next earnings event is flagged for November 13 — making the weeks ahead a test of whether bulls can maintain momentum through a quiet news window while bears nurse a position that has cost them dearly this week.
See the live data behind this article on ORTEX.
Open TWST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
